CHD1是MYC驱动的乳腺癌中的合成致命漏洞
Brandon Cho1,2, Giacomo Furlan1, Peter Lin3,4
1Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
Oncogene
|March 7, 2026
概括
失去了CHD1,一种染色体重塑剂,是MYC驱动的乳腺癌中合成致命的标. 抑制CHD1通过诱导细胞死亡和核细胞应激抑制瘤生长,提供了一个新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 染色体生物学 染色体生物学
背景情况:
- MYC转录因子对细胞生长至关重要,但在失调时会导致癌症.
- 直接针对MYC已经证明具有挑战性,需要替代治疗策略.
- 了解MYC的致癌机制是开发新的癌症治疗方法的关键.
研究的目的:
- 在MYC驱动的乳腺癌中确定新的治疗点.
- 研究染色体重塑在MYC驱动的癌症中的作用.
- 探索涉及MYC的合成致命相互作用.
主要方法:
- 全基因组屏幕识别潜在的合成致命目标.
- 在体外细胞培养模型评估细胞增殖和细胞死亡.
- 在体内异种移植模型评估瘤生长抑制.
- 对染色体景观和转录程序的机制研究.
主要成果:
- 染色体-酶DNA结合1 (CHD1) 的损失被确定为MYC驱动的乳腺癌中的合成致命标.
- 抑制CHD1抑制了体内瘤生长,减少了体内细胞增殖/诱导细胞死亡,特别是当MYC过度表达时.
- 在MYC过度表达细胞中,CHD1保持着开放的染色质状态和促癌转录程序.
- 合成致死性似乎是由核子应激和p53激活引起的.
结论:
- 在MYC驱动的乳腺癌中,CHD1对于维持恶性表型至关重要.
- CHD1代表了一种新的合成脆弱性和MYC驱动的乳腺癌的潜在治疗标.
- 这些发现为MYC驱动的瘤发生中的染色体调节提供了新的见解.
相关概念视频
Induced Pluripotent Stem Cells
5.8K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
5.8K
Abnormal Proliferation
5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Mouse Models of Cancer Study
6.6K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
6.6K
The Intrinsic Apoptotic Pathway
9.0K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.0K
Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K


